Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study of tucatinib (ONT-380) in combination with Kadcyla in patients with breast cancer who have a history of central nervous system (CNS) metastases.

Trial Profile

Phase 3 study of tucatinib (ONT-380) in combination with Kadcyla in patients with breast cancer who have a history of central nervous system (CNS) metastases.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tucatinib (Primary) ; Trastuzumab emtansine
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Sponsors Cascadian Therapeutics

Most Recent Events

  • 09 Mar 2018 According to a Seattle Genetics media release, Cascadian Therapeutics has been acquired by Seattle Genetics, and this acquisition provides the Global Rights of Tucatinib to Seattle Genetics.
  • 11 Dec 2015 New trial record
  • 08 Dec 2015 According to Oncothyreon media release,company is planning to discuss about the designs of this trial, together with the overall registration strategy, with the regulatory authorities that includes the US FDA, in the first part of 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top